FDP, Palantir and Global Counsel: Under Mandelson's Long Shadow

Why It Matters

If political patronage helped secure a multi‑billion‑pound NHS data contract, it erodes public trust and heightens data‑governance risks. Strengthening procurement standards is essential to protect the integrity of the UK health system.

Key Takeaways

• Palantir won NHS FDP contract in 2023
• Palantir hired Global Counsel, co‑founded by Peter Mandelson
• Mandelson was sacked as US ambassador over Epstein links
• Lobbying ties raise conflict‑of‑interest concerns for NHS procurement
• Letter calls for ethical, ESG‑based NHS procurement policy

Pulse Analysis

Palantir Technologies, best known for its data‑integration platforms, secured a high‑profile contract to build the NHS Federated Data Platform in 2023. The FDP is intended to unify patient records across England, promising faster analytics and cost savings. Yet the project has been mired in criticism over transparency, data security, and the suitability of a U.S. firm handling sensitive health information. Critics argue that the contract’s value—potentially exceeding £1 billion (≈ $1.25 billion)—was awarded with limited public scrutiny, fueling a broader debate about foreign tech involvement in Britain’s public services.

Complicating the controversy is Palantir’s engagement of Global Counsel, a lobbying boutique co‑founded by Peter Mandelson, a former Labour cabinet minister and peer. Mandelson’s recent removal as the UK ambassador to the United States—citing undisclosed connections to convicted sex offender Jeffrey Epstein—has intensified scrutiny of his lingering influence. While Mandelson resigned from Global Counsel’s board in 2024, his extensive network within Westminster may have facilitated introductions that smoothed Palantir’s path to the FDP deal. The episode underscores how lobbying firms can act as conduits between corporate interests and government procurement, raising red flags about possible conflicts of interest.

The fallout highlights a pressing need for the NHS to embed ethical, ESG‑driven criteria into its procurement framework. An explicit policy would require vendors to meet standards on data privacy, sustainability, and corporate governance before contract eligibility. Such safeguards could restore public confidence, deter undue political leverage, and ensure that future digital health initiatives prioritize patient safety over commercial gain. As the UK grapples with post‑Brexit tech strategy, transparent procurement will be a cornerstone of a resilient, trustworthy health system.